Vaccitech Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 43
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $13.4M
Latest Deal Amount
  • Investors
  • 13

Vaccitech General Information

Description

Developer of therapeutic vaccine technology designed to provide treatment for seasonal flu and prostate cancer. The company's technology includes live-attenuated, killed whole-cell and subunit antigen vaccines that deliver either one or two heterologous viral vector vaccines, each encoding the same antigen, enabling healthcare professionals to prevent influenza and treat prostate cancer and improve the protection provided by the seasonal flu vaccination.

Contact Information

Website
www.vaccitech.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • The Schrodinger Building, Heatley Road
  • The Oxford Science Park
  • Oxford OX4 4GE
  • England, United Kingdom
+44 01865 000000

Vaccitech Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaccitech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC 26-Dec-2020 $13.4M 000.00 Completed Clinical Trials - General
5. Grant 27-Aug-2020 00000 000.00 Completed Clinical Trials - General
4. Grant 07-Mar-2019 00.00 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series A) 20-Dec-2018 00.000 000.00 000.00 Completed Clinical Trials - General
2. Early Stage VC (Series A) 14-Jan-2018 $27M $41.5M 000.00 Completed Clinical Trials - General
1. Seed Round 10-May-2016 $14.6M $14.6M 000.00 Completed Clinical Trials - General
To view Vaccitech’s complete valuation and funding history, request access »

Vaccitech Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 0,000 00.000000 00000.00 00000.00 00 00000.00 0.000
Series A 00,000 00.000000 00000.00 00000.00 00 00000.00 00.000
Ordinary 13,333 $0.012718 $953.81 $953.81 1x $953.81 29.28%
Ordinary 133 $0.012718 $956.2 $956.2 1x $956.2 0.29%
To view Vaccitech’s complete cap table history, request access »

Vaccitech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic vaccine technology designed to provide treatment for seasonal flu and prostate cancer. The comp
Drug Discovery
Oxford, United Kingdom
43 As of 2021
000.00
0000000000 0 000.00

00000000

lore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000 000000000
Ottawa, Canada
00 As of 0000
00000
000000000000 00000

000000

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000 000000000
Seattle, WA
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vaccitech Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Turnstone Biologics Venture Capital-Backed Ottawa, Canada 00 00000 000000000000 00000
000000 Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
000 0000000000000 Formerly VC-backed Princeton, NJ 00 00.000 000000 - 000 00.000
00000000 000000000 Venture Capital-Backed Uppsala, Sweden 00 0000000000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 35 competitors. Get the full list »

Vaccitech Executive Team (10)

Name Title Board Seat Contact Info
Georgy Egorov Chief Financial Officer
Chris Ellis Chief Operating Officer
Thomas Evans MD Chief Scientific Officer, Board Member & CMO
Graham Griffiths Chief Business Officer
Adrian Hill Co-Founder & Scientific Advisor
You’re viewing 5 of 10 executive team members. Get the full list »

Vaccitech Board Members (8)

Name Representing Role Since
Alex Hammacher Self Board Member 000 0000
Andrew McLean MD Oxford Sciences Innovation Board Member 000 0000
Pierre Morgon Self Board Member 000 0000
Robin Wright Self Chairman 000 0000
Thomas Evans MD Vaccitech Chief Scientific Officer, Board Member & CMO 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Vaccitech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vaccitech Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Future Planet Capital Growth/Expansion Minority 000 0000 000000 0
UK Research and Innovation Government 000 0000 000000 0
Biomedical Advanced Research and Development Authority Corporation 000 0000 000000 0
Genematrix Corporation Minority 000 0000 000000 0
Korea Investment Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial